EODData

MEMBERSHIP REGISTER LOG IN

FRA, NNFN: MannKind Corporation

02 Oct 2025
LAST:

4.525

CHANGE:
 0.11		OPEN:
4.525		HIGH:
4.525		ASK:
0.000		VOLUME:
2K
CHG(%):
2.51		PREV:
4.414		LOW:
4.525		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
02 Oct 254.5254.5254.5254.5252K
01 Oct 254.4144.4144.4144.4140
30 Sep 254.5254.5594.5254.5590
29 Sep 254.6624.6624.6624.662500
26 Sep 254.4974.4974.4974.497500
25 Sep 254.3984.3984.3984.398500
24 Sep 254.4784.4784.4784.478500
23 Sep 254.6684.6684.6684.668500
22 Sep 254.5544.5544.5544.554500
19 Sep 254.7014.7014.7014.701500

COMPANY PROFILE

Name:MannKind Corporation
About:MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Sector:Healthcare
Industry:Biotechnology
Address:1 Casper Street, Danbury, CT, United States, 06810
Website:https://www.mannkindcorp.com
ISIN:US56400P7069
LEI:213800GFBCNY1ZFST722

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:54.46
Price to Sales:4.98
EBITDA:81.21M
Shares:306.83M
Market Cap:1.388B

TECHNICAL INDICATORS

MA5:4.53
MA10:4.55
MA20:4.58
MA50:3.90
MA100:3.66
MA200:4.35
STO9:47.04
STO14:41.91
RSI14:45.13
WPR14:-58.09
MTM14:-0.04
ROC14:-0.01
ATR:0.13
Week High:4.66
Week Low:4.40
Month High:5.00
Month Low:3.86
Year High:7.00
Year Low:2.93

RECENT SPLITS

Date Ratio
03 Mar 20171-5